ArriVent Biopharma Files 8-K for Bylaw Amendments, Other Events
Ticker: AVBP · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1868279
| Field | Detail |
|---|---|
| Company | Arrivent Biopharma, INC. (AVBP) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $18.00, $175.0 m |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, bylaws, amendment, compliance
TL;DR
**ArriVent Biopharma filed an 8-K for corporate governance updates, signaling routine compliance.**
AI Summary
ArriVent Biopharma, Inc. filed an 8-K on January 30, 2024, to report an amendment to its Articles of Incorporation or Bylaws, along with other events and financial statements. This filing indicates a routine corporate governance update, likely related to its Common Stock, $0.0001 par value per share, which trades under the symbol 'AVBP'. For investors, this matters because it signals ongoing compliance and operational adjustments, which are generally positive for a company's stability and transparency.
Why It Matters
This filing indicates ArriVent Biopharma is making standard corporate governance updates, which is a sign of an active and compliant public company. It provides transparency into the company's operational and structural changes.
Risk Assessment
Risk Level: low — This 8-K filing appears to be a routine corporate update with no immediate indication of significant positive or negative financial impact.
Analyst Insight
A smart investor would view this as a routine compliance filing, indicating no immediate need for action but reinforcing the company's ongoing operational status. It's a data point for general corporate health rather than a catalyst for significant price movement.
Key Numbers
- $0.0001 — par value per share (par value of ArriVent Biopharma's Common Stock)
Key Players & Entities
- ArriVent Biopharma, Inc. (company) — the registrant filing the 8-K
- January 30, 2024 (date) — date of earliest event reported and filing date
- $0.0001 (dollar_amount) — par value per share of Common Stock
- AVBP (company) — trading symbol for ArriVent Biopharma's Common Stock
Forward-Looking Statements
- ArriVent Biopharma will continue to make routine corporate governance filings. (ArriVent Biopharma, Inc.) — high confidence, target: 2025-01-30
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 30, 2024, which is also the date the report was filed.
What specific items were reported under 'ITEM INFORMATION' in this 8-K?
The specific items reported under 'ITEM INFORMATION' were 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year', 'Other Events', and 'Financial Statements and Exhibits'.
What is the par value of ArriVent Biopharma, Inc.'s Common Stock?
The par value of ArriVent Biopharma, Inc.'s Common Stock is $0.0001 per share.
What is the trading symbol for ArriVent Biopharma, Inc.'s Common Stock?
The trading symbol for ArriVent Biopharma, Inc.'s Common Stock is AVBP.
Where is ArriVent Biopharma, Inc.'s principal executive office located?
ArriVent Biopharma, Inc.'s principal executive office is located at 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073.
Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-01-30 16:05:22
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share AVBP The Nasdaq
- $18.00 — mon stock at a public offering price of $18.00 per share. The gross proceeds to the Co
- $175.0 m — Company from the IPO were approximately $175.0 million, before deducting underwriting di
Filing Documents
- tm2321853d25_8k.htm (8-K) — 28KB
- tm2321853d25_ex3-1.htm (EX-3.1) — 49KB
- tm2321853d25_ex3-2.htm (EX-3.2) — 120KB
- 0001104659-24-008228.txt ( ) — 409KB
- avbp-20240130.xsd (EX-101.SCH) — 3KB
- avbp-20240130_lab.xml (EX-101.LAB) — 33KB
- avbp-20240130_pre.xml (EX-101.PRE) — 22KB
- tm2321853d25_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ARRIVENT BIOPHARMA, INC. By: /s/ Winston Kung, MBA Winston Kung, MBA Chief Financial Officer and Treasurer Date: January 30, 2024